Effects of statins on renal sodium and water handling
|
|
- Nancy Cain
- 6 years ago
- Views:
Transcription
1 Nephrol Dial Transplant (2008) 23: doi: /ndt/gfm807 Advanced Access publication 8 December 2007 Original Article Effects of statins on renal sodium and water handling Acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans Lone Paulsen 1, Charlotte Holm 1, Jesper Nørgaard Bech 2, Jørn Starklint 1 and Erling Bjerregaard Pedersen 1,2 1 Department of Medical Research, Holstebro Hospital and Aarhus University, Denmark and 2 Department of Medicine, Holstebro Hospital, Holstebro, Denmark Abstract Background. Statins have a beneficial effect on cardiovascular morbidity and mortality due to a reduction in plasma cholesterol. However, statins seem to have effects beyond the lowering of plasma cholesterol. We hypothesize that these effects are caused by an effect on renal function. Methods. We measured the effects of atorvastatin (AS) on renal function in two randomized, placebo-controlled, double-blinded and crossover studies in healthy man. In an acute trial (Study 1), 19 subjects received either 80 mg AS as a single dose or placebo. In a short-term trial (Study 2), 20 subjects received either 80 mg AS or placebo daily for 4 weeks. In both studies glomerular filtration rate (GFR), renal plasma flow (RPF), plasma concentrations of angiotensin II (Ang II), renin (PRC), atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), aldosterone (Aldo), vasopressin (AVP) and blood pressure (BP) were determined. Results. In Study 1 AS decreased fractional excretion of sodium (FE Na ) significantly (P = 0.035), but very modestly, and reduced diastolic BP (P = 0.024). Apart from this, we found no significant differences in GFR, RPF, tubular function and vasoactive hormones in either Study 1 or 2. Conclusions. An acute dose of AS decreased FE Na and DBP in healthy humans. The reduction in fractional urinary sodium excretion was very modest and transitory, and most likely secondary to the fall in diastolic blood pressure (DBP). However, renal haemodynamics, tubular function, vasoactive hormones and blood pressure were unchanged during short-term statin treatment in healthy man. Keywords: atorvastatin; glomerular filtration rate; healthy humans; renal plasma flow; sodium excretion Correspondence and offprint requests to: Lone Paulsen, Department of Medical Research, Holstebro Hospital, Lægårdvej 12, DK-7500 Holstebro, Denmark. Tel: ; Fax: ; 55@stofanet.dk Introduction Statin therapy is associated with reductions in cardiovascular morbidity and mortality [1,2]. The beneficial effects of statins are cholesterol lowering, but other non-lipiddependent (pleiotropic) effects may largely account for the clinical benefits of these agents. Pleiotropic effects have important clinical implications for the cardiovascular system and may include a beneficial effect on kidney function beyond their lipid-ameliorating action as well. In rats and pigs, statins prevented the development of renal injury and enhanced renal perfusion [3,4]. In patients with cardiovascular disease and moderate to severe kidney disease, statins reduce proteinuria and kidney function loss [5,6]. In patients with autosomal dominant polycystic kidney disease treatment with simvastatin increases glomerular filtration rate (GFR), renal plasma flow (RPF) and endothelial function, probably explained by the direct effect of statins on NO production [7]. No information is available about the acute and short-term effects of atorvastatin (AS) on renal function and blood pressure in healthy humans. For the first time, we investigated the effect of AS on renal salt and water handling in healthy subjects. We performed two randomized, placebo-controlled, crossover studies of the acuteand short-term effect of AS in healthy man. The purpose was to measure the effect of AS on renal haemodynamics, tubular function, vasoactive hormones and blood pressure. We wanted to test the hypothesis that treatment with a single dose of AS in an acute (Study 1) and short-term trial, i.e. 4 weeks of treatment with AS (Study 2) changes renal function. Improvements of renal function may explain some of the pleiotropic effects of statins. Subjects and methods Subjects The inclusion criteria in both studies were (1) age years, (2) body mass index <30. The following were C The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org
2 Effects of statins on renal sodium and water handling 1557 considered as exclusion criteria in both studies: (1) a history or clinical signs of disease of the heart, lungs, kidneys or endocrine organs; (2) abnormal laboratory screening tests (i.e. abnormal b-haemoglobin, p-sodium, p- potassium, p-albumin, p-creatinine, p-glucose, p-bilirubin, p-alaninaminotransferasis and p-alkaline phosphatase, albuminuria or glucosuria); (3) malignant neoplasm; (4) hypertension; (5) alcohol abuse: (6) medical therapy apart from oral contraceptives; (7) pregnancy or breast feeding; (8) blood donation <1 month before the studies. Withdrawal criteria in both studies included the following: (1) development of one or more of the exclusion criteria, (2) side effects of AS or other used drugs during the study, (3) poor compliance and (4) unwillingness to participate. Ethics The local medical ethics committee approved both studies and were carried out according to their rules. Written informed consent was obtained from all participants. Design Both studies were randomized, double-blinded, placebocontrolled and crossover. In Study 1, healthy subjects received 80 mg AS or placebo per os in the morning of the experimental day. In Study 2, healthy subjects received 80 mg AS or placebo per os daily for 4 weeks. There was a time interval of at least 4 weeks between the two experimental days in both studies. Number of subjects In both studies, the number of subjects needed was calculated at a significance level of 5% and with a power of 90%. For RPF, the minimum relevant difference was estimated to be 30 ml/min and the corresponding SD was estimated to be 40 ml/min. Thus, subjects were needed. Recruitmen of subjects In both studies, healthy subjects were recruited by announcements and notices in public institutions and private companies in the city of Holstebro, Denmark. Experimental procedure In Study 1, the subjects were instructed to fast overnight before each of the experimental days, but were allowed to drink water freely until the beginning of the study. A 24-h urine collection was performed the day before the study day and the subjects received 300 mg lithiumcarbonate at 22:00 h for measurement of lithium clearance. The subjects drank a glass of tap water before they met in the Research Laboratory at 07:45 h. Smoking was prohibited during the study. The subjects were in the supine position during the experimental period until 14:30 h, apart from when voiding. The subjects received 80 mg AS or placebo per os at 08:00 h. Indwelling catheters were placed in both forearms, one for infusion of 51 Cr EDTA and 125 I hippuran and one for withdrawal of blood samples. The subjects drank a glass of water (175 ml) every half hour. At 08:30 h, we infused a priming dose of 51 Cr-labelled EDTA and 125 I-labelled hippuran for the measurement of GFR and RPF, followed by constant infusions of both. Nine clearance periods were performed each of 30 min duration between 10:00 and 14:30 h. Urine was collected for measurement of sodium, lithium, volume, 51 Cr EDTA, 125 I hippuran and osmolarity in each period. Blood samples were drawn at the end of each clearance period for measurement of plasma concentrations of sodium, lithium, 51 Cr EDTA, 125 I hippuran and osmolarity. Blood samples were drawn at 11:30, 12:30, 13:30 and 14:30 h to determine plasma concentrations of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), aldosterone (Aldo), vasopressin (AVP), angiotensin II (Ang II) and renin (PRC). BP and PR were measured every 30 min throughout the study. The subjects were weighed before and after the study. The experimental procedure in Study 2 was the same as in Study 1, except that five clearance periods were performed instead of nine between 10:00 and 12:30 h, blood samples for analysis of hormones were drawn once at 11:30 h instead of four times and endothelin-1 (ET- 1) in plasma and aquaporin 2 in urine (u-apq2) were measured. Measurements We measured GFR and RPF using the renal clearance of 51 Cr EDTA and 125 I hippuran by a constant infusion technique. ANP, BNP, AVP and Ang II in plasma were determined by radioimmunoassay as previously described [8,9]. Aldo was determined using a kit from Diagnostic Systems Laboratories Inc. (TX, USA). PRC was measured with a commercial immunoradiometric assay (Nichols Institute Diagnostics, Paris, France). U-AQP2 was measured by radioimmunoassay, as previously described [10]. ET-1 was measured by immunoassay (R&D Systems, Inc., Minneapolis, MN, USA). Minimal detection level was <1.0 pg/ml. Plasma and urinary lithium (P-Li, U-Li) were measured by atomic absorption spectrometry. Plasma osmolality (P-osm) and U-osm were measured by freezing-point depression (Advanced Instruments, Inc. The Advanced Model 3900, multisampling osmometer). Plasma and urinary concentrations of sodium (P-Na, U-Na) were measured by routine methods at the Department of Clinical Biochemistry, Holstebro Hospital (Holstebro, Denmark). BP and PR were determined using a digital blood pressure meter. All clearances were standardized to a body surface area of 1.73 m 2. Statistics SPSS, version 13.0 was used for the statistical analyses. Friedman s test was used for paired comparison between several groups. Wilcoxon s signed rank test was used for paired comparison between two groups, i.e. of the mean values of the results from each of the clearance periods during AS and placebo treatment, respectively. Data are given as medians with quartiles. The significance level was at P = 0.05.
3 1558 L. Paulsen et al. Table 1. The effect of acute treatment with atorvastatin (80 mg) compared to placebo (Study 1), and the effect of short-term treatment for 4 weeks with atorvastatin (80 mg) daily compared to placebo (Study 2) in healthy subjects Study 1 (n = 19) Study 2 (n = 20) Atorvastatin Placebo P Atorvastatin Placebo P V (ml/min) ( ) ( ) NS ( ) ( ) NS (C H2 O) (ml/min) ( ) ( ) NS ( ) ( ) NS C Na (ml/min) ( ) ( ) NS ( ) ( ) NS FE Na ( ) ( ) ( ) ( ) NS C Li (ml/min) ( ) ( ) NS ( ) ( ) NS FE Li ( ) ( ) NS ( ) ( ) NS U Na V(µmol/min) ( ) ( ) NS ( ) ( ) NS The effect variables were urine output (V), free water clearance (C H2 O), sodium clearance (C Na ), fractional excretion of sodium (FE Na ), clearance of lithium (C Li ), fractional excretion of lithium (FE Li ) and absolute sodium excretion (U Na V). Nine clearance periods were performed in Study 1 and five periods in Study 2. The mean values of the effect variables for the nine and five clearance periods are given for the AS and placebo periods in Study 1 and 2, respectively. Friedman s test did not show significant differences in the effect variables between the clearance periods either during atorvastatin or placebo treatment in neither Study 1 nor 2. Wilcoxon s test was used for comparison of medians. Data are given as medians with 25 and 75 percentiles. Results Demographics In Study 1, 19 healthy subjects were included: (1) males/females (14/5); (2) age, 31 years (26 39); (3) BMI, 23.8 ( ); (4) systolic blood pressure (SBP), mmhg, 112 ( ); (5) diastolic blood pressure (DBP), mmhg, 68 (65 73); (6) pulse rate, beats/min, 52 (49 61). All routine laboratory tests were normal. In Study 2, 20 healthy subjects were included: (1) males/females (13/7); (2) Age, 32 years (26 43); 3. BMI, 25.3 ( ); (4) SBP, mmhg, 109 ( ); (5) DBP, mmhg, 68 (60 74); (6) pulse rate, beats/min, 53 (49 57). All routine laboratory tests were normal. Baseline and laboratory characteristics for healthy subjects in Study 1 and 2 are given as medians with 25 and 75 percentiles. Renal haemodynamics A single dose of AS did not change GFR (ml/min) [AS: 92 (89 105); placebo 94 (87 104), P = NS], RPF (ml/min) [AS: 445 ( ); placebo 455 ( ), P = NS], or the filtration fraction (FF) [AS: ( ); placebo ( ), P = NS]. Neither did treatment with AS for 4 weeks change GFR (ml/min) [AS: 102 (92 108); placebo 100 (96 110), P = NS], RPF (ml/min) [AS: 459 ( ); placebo 473 ( ), P = NS], nor did it change the FF [AS: ( ); placebo ( ), P = NS]. Data are given as medians with 25 and 75 percentiles. Tubular function Table 1 shows that the fractional excretion of sodium (FE Na ) was significantly lower in the AS-treated group compared to the placebo group in Study 1 [AS: ( ); placebo: ( ), P = 0.035]. The reduction in FE Na by AS was very modest, and FE Na was unchanged in Study 2. Table 3 shows also that neither AS given acutely nor short-term induced any significant changes in V, C H2 O,C Na, C Li and FE Li. AS given for 4 weeks showed no significant changes in u-aqp2 [AS: 0.82 ( ) ng/ml; placebo: 0.79 ( ) ng/ml]. 24-h sodium excretion The 24-h urinary sodium excretion [AS: 204 ( ) mmol/24 h; placebo: 205 ( ) mmol/24 h] and urinary sodium/urinary creatinine ratio [AS: ( ); placebo: ( )] were not changed significantly after AS. However, in the shortterm study 24-h urinary sodium excretion was 26% lower in the AS-treated group compared to placebo [AS: 167 ( ) mmol/24 h; placebo: 225 ( ) mmol/24 h, P = 0.005]. This difference was also present when urinary sodium excretion was evaluated in relation to urinary creatinine excretion [AS: ( ); placebo: ( ), P = 0.028]. Vasoactive hormones Table 2 shows that no significant changes were measured in ANP, BNP, Aldo, AVP, Ang II and PRC after AS treatment in neither the acute nor the short-term study. AS given for 4 weeks showed no significant changes in ET-1 [AS: 0.65 ( ) pg/ml; placebo: 0.65 ( ) pg/ml] either. Blood pressure Table 3 shows that the DBP was significantly decreased by AS [AS: 62 (59 71) mmhg; placebo: 65 (62 71) mmhg, P = 0.024] in Study 1, whereas we found no significant
4 Effects of statins on renal sodium and water handling 1559 Table 2. The effects of a single dose of atorvastatin (80 mg) compared to placebo (Study 1) and 4-weeks treatment with atorvastatin (80 mg) daily compared to placebo (Study 2) in healthy subjects on plasma concentration of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), aldosterone (Aldo), vasopressin (AVP), angiotensin II (Ang II) and renin (PRC) Study 1 (n = 19) Study 2 (n = 20) Atorvastatin Placebo P Atorvastatin Placebo P ANP (pmol/l) ( ) ( ) NS ( ) ( ) NS BNP (pmol/l) ( ) ( ) NS ( ) ( ) NS Aldo (pmol/l) ( ) ( ) NS ( ) ( ) NS AVP (pmol/l) ( ) ( ) NS ( ) ( ) NS Ang II (pmol/l) (9 22) (10 19) NS (5 13) (6 13) NS PRC (µmol/l) (14 30) (12 32) NS (13 24) (10 23) NS In Study 1 hormones were measured four times during nine clearance periods. In Study 2 hormones were measured once during five clearance periods. The mean values of the effect variables are given for the AS and placebo periods in Study 1 and 2, respectively. Friedman s test did not show significant differences in the effect variables between the clearance periods either during atorvastatin or placebo treatment in neither Study 1 or 2. Wilcoxon s test was used for comparison of medians. Data are given as medians with 25 and 75 percentiles. Table 3. The effects of a single dose of atorvastatin (80 mg) compared to placebo (Study 1) and 4-weeks treatment with atorvastatin (80 mg) daily compared to placebo (Study 2) in healthy subjects on systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) and pulse rate (PR) Study 1 (n = 19) Study 2 (n = 20) Atorvastatin Placebo P Atorvastatin Placebo P SBP (mmhg) ( ) ( ) NS ( ) ( ) NS DBP (mmhg) (59 71) (62 71) (60 71) (61 72) NS MAP (mmhg) (74 86) (77 86) NS (75 85) (76 87) NS PR (beats/min) (48 59) (49 60) NS (52 60) (53 62) NS Effect variables were measured corresponding to nine clearance periods in Study 1 and five periods in Study 2. The mean values of the effect variables for the nine and five clearance periods are given for the AS and placebo periods in Study 1 and 2, respectively. Friedman s test did not show significant differences in the effect variables between the clearance periods either during atorvastatin or placebo treatment in neither Study 1 nor 2. Wilcoxon s test was used for comparison of medians. Data are given as medians with 25 and 75 percentiles. differences in the SBP. AS did not change SBP or DBP in Study 2. Discussion The present report comprises two randomized, placebocontrolled, crossover studies of the acute and short-term effect of AS in healthy man on renal haemodynamics, tubular function, vasoactive hormones and blood pressure. AS induced a very modest, although significant reduction in fractional renal excretion of sodium and a fall in DBP in our acute study, whereas SBP was unchanged. AS reduced 24-h urinary excretion of sodium in the short-term study and blood pressure was unchanged. Renal haemodynamics and vasoactive hormones were the same after statin treatment and placebo in both studies. Statins seem to influence blood pressure regulation under certain conditions. Thus, development of hypertension is prevented or postponed in spontaneous hypertensive rats [11], and an antihypertensive effect of statins has been shown in hypertensive patients [12]. DBP decreased slightly in the present study of the acute effect of AS treatment. However, statin treatment did not change blood pressure in the short-term study of 1 month s duration. It seems reasonable to conclude that systemic blood pressure is unaffected by treatment with statins in normotensive subjects. In rats, GFR and renal blood flow increased after treatment with a statin [11]. Statin treatment improved renal function in patients with ischaemic heart disease and in patients with autosomal dominant polycystic kidney disease [7,13]. However, in another study statin treatment did not induce significant changes in GFR or RPF [14].
5 1560 L. Paulsen et al. We found no changes in either GFR or RPF in healthy man in the present study. Thus, in healthy man, statin treatment does not induce significant alterations in renal haemodynamics. In animal experiments, lovastatin increased urine flow, renal sodium excretion and FE Na in spontaneously hypertensive rats [11]. We are the first to study the effect of statins on renal salt and water handling in healthy subjects. We found a very modest reduction in FE Na in the acute study, in contrast to studies in rats [11]. However, AS reduced DBP simultaneously in our study. Most likely, this increased tubular reabsorption of sodium is a transitory phenomenon and secondary to the reduction in blood pressure, and this effect disappeared in the short-term study. Surprisingly, we found a decrease in 24-h urinary sodium excretion in the short-term study, i.e. after 4 weeks of treatment with AS compared to placebo. This difference was also present when we calculated urinary sodium excretion in relation to urinary excretion of creatinine to eliminate a potential loss of urine during the 24-h urine collection. The body weight was the same after AS treatment and placebo for 1 month; thus, sodium and/or water depletion is unlikely. The subjects studied received an unrestricted diet with regard to sodium, water and food intake, and the difference in urinary sodium excretion might reflect variation in sodium intake, which varied considerably according to the variation in urinary sodium excretion at the examinations after placebo as well as after AS treatment. Since C H2 O,C Na,FE Na,C Li,FE Li and u-aqp2 all give some evaluation of tubular function directly or indirectly and since AS did not change any of these effect variables during 1 month of therapy, we have shown that AS does not affect renal tubular function at least in a short-term evaluation. Previous studies have shown that statins reduced plasma concentration levels of ANP [15], BNP [16], Aldo [17], AVP [18], Ang II [19] and ET-1 [15], whereas simvastatin did not change PRC [17]. We showed that AS did not change any of the vasoactive hormones measured in the acute or the short-term study. However, we studied healthy man, and the effect of statins on these hormones might differ between diseases, in which the regulation of the hormones can be abnormal primarily or secondarily to the disease or its complications. Statins differ with regard to lipophilicity and metabolism that may explain differences between studies of statins effect in different populations and in different vascular areas [20]. In conclusion, we demonstrated that the acute effect of AS treatment was a very modest and transitory reduction in fractional urinary sodium excretion, most likely secondary to a decrease in DBP in healthy subjects. However, renal haemodynamics, tubular function, vasoactive hormones and blood pressure were unchanged during short-term statin treatment in healthy man. Acknowledgements. We thank laboratory technicians Lisbeth Mikkelsen, Henriette Hedelund Vorup Simonsen, Anne Mette Ravn Torstensen, Eva Mølgaard Jensen and Susan Milton Rasmussen for skillful technical assistance and commitment. The study received support by grants from Ringkjoebing County and the Foundation for Medical Research in the County of Ringkjoebing. Conflict of interest statement. None declared. References 1. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999; 20: Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: Kido M, Ando K, Oba S et al. Renoprotective effect of pravastatin in salt-loaded Dahl salt-sensitive rats. Hypertens Res 2005; 28: Wilson SH, Chade AR, Feldstein A et al. Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolaemia. Nephrol Dial Transplant 2003; 18: Sandhu S, Wiebe N, Fried LF et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006; 17: Tonelli M, Moye L, Sacks FM et al. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003;14: van Dijk MA, Kamper AM, van VS et al. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001; 16: Pedersen EB, Eiskjaer H, Madsen B et al. Effect of captopril on renal extraction of renin, angiotensin II, atrial natriuretic peptide and vasopressin, and renal vein renin ratio in patients with arterial hypertension and unilateral renal artery disease. Nephrol Dial Transplant 1993; 8: Jensen KT, Carstens J, Ivarsen P et al. A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. Scand J Clin Lab Invest 1997; 57: Pedersen RS, Bentzen H, Bech JN et al. Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans. Am J Physiol Renal Physiol 2001; 280: F860 F Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997; 30: Milionis HJ, Liberopoulos EN, Achimastos A et al. Statins: another class of antihypertensive agents? J Hum Hypertens 2006; 20: Athyros VG, Mikhailidis DP, Liberopoulos EN et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: Atthobari J, Brantsma AH, Gansevoort RT et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 2006; 21: Strey CH, Young JM, Lainchbury JH et al. Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart 2006; 92: Emberson JR, Ng LL, Armitage J et al. N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. JAmColl Cardiol 2007; 49:
6 Effects of statins on renal sodium and water handling IdeH, Fujiya S, Aanuma Yet al. Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones. Clin Ther 1990; 12: Ishikawa S, Kawasumi M, Saito T. Simvastatin inhibits the cellular signaling and proliferative action of arginine vasopressin in cultured rat glomerular mesangial cells. Endocrinology 1995;136: Van Der Linde NA, Sijbrands EJ, Boomsma F et al. Effect of lowdensity lipoprotein cholesterol on angiotensin II sensitivity: a randomized trial with fluvastatin. Hypertension 2006; 47: Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19: Received for publication: Accepted in revised form:
Janni M Jensen 1,2*, Frank H Mose 1,2, Jesper N Bech 1,2, Soren Nielsen 3 and Erling B Pedersen 1,2
Jensen et al. BMC Nephrology 2013, 14:202 RESEARCH ARTICLE Open Access Effect of volume expansion with hypertonic- and isotonic saline and isotonic glucose on sodium and water transport in the principal
More informationSUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics
Supplementary Table 1. Baseline Patient Characteristics Normally distributed data are presented as mean (±SD), data that were not of a normal distribution are presented as median (ICR). The baseline characteristics
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy
Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All hypercholesterolaemic diabetics
More informationIn nocturnal enuresis
The role of the kidney In nocturnal enuresis Kostas Kamperis MD PhD Dept of Pediatrics, Section of Nephrology Aarhus University Hospital, Aarhus, Denmark Enuresis prototypes Nocturnal polyuria Bladder
More informationInflammation in Renal Disease
Inflammation in Renal Disease Donald G. Vidt, MD Inflammation is a component of the major modifiable risk factors in renal disease. Elevated high-sensitivity C-reactive protein (hs-crp) levels have been
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationResearch Article The Effects of Simvastatin on Proteinuria and Renal Function in Patients with Chronic Kidney Disease
International Nephrology Volume 2015, Article ID 485839, 6 pages http://dx.doi.org/10.1155/2015/485839 Research Article The Effects of Simvastatin on Proteinuria and Renal Function in Patients with Chronic
More informationPatterns of Sodium Excretion During Sympathetic Nervous System Arousal. Gregory A. Harshfield, Derrick A. Pulliam, and Bruce S.
1156 Patterns of Sodium Excretion During Sympathetic Nervous System Arousal Gregory A. Harshfield, Derrick A. Pulliam, and Bruce S. Alpert The purpose of this study was to examine Na + handling and regulation
More informationRole of Minerals in Hypertension
Role of Minerals in Hypertension Lecture objectives By the end of the lecture students will be able to Define primary and secondary hypertention and their risk factors. Relate role of minerals with hypertention.
More informationSupplementary Online Content
Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure
More informationDirect effect of methylprednisolone on renal sodium and water transport via the principal cells in the kidney
European Journal of Endocrinology (2010) 162 961 969 ISSN 0804-4643 CLINICAL STUDY Direct effect of methylprednisolone on renal sodium and water transport via the principal cells in the kidney Thomas G
More informationRenal-Related Questions
Renal-Related Questions 1) List the major segments of the nephron and for each segment describe in a single sentence what happens to sodium there. (10 points). 2) a) Describe the handling by the nephron
More informationEffects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II III chronic kidney disease
British Journal of Clinical Pharmacology DOI:10.1111/bcp.12390 Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II III chronic kidney disease Frank Holden
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationBlood Pressure Regulation 2. Faisal I. Mohammed, MD,PhD
Blood Pressure Regulation 2 Faisal I. Mohammed, MD,PhD 1 Objectives Outline the intermediate term and long term regulators of ABP. Describe the role of Epinephrine, Antidiuretic hormone (ADH), Renin-Angiotensin-Aldosterone
More informationBlood Pressure Regulation 2. Faisal I. Mohammed, MD,PhD
Blood Pressure Regulation 2 Faisal I. Mohammed, MD,PhD 1 Objectives Outline the intermediate term and long term regulators of ABP. Describe the role of Epinephrine, Antidiuretic hormone (ADH), Renin-Angiotensin-Aldosterone
More informationSafa Al Therwani *, My Emma Sofie Malmberg, Jeppe Bakkestroem Rosenbaek, Jesper Noergaard Bech and Erling Bjerregaard Pedersen
Al Therwani et al. BMC Nephrology (2017) 18:268 DOI 10.1186/s12882-017-0686-3 RESEARCH ARTICLE Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant
More informationPaul M McKie, Alessandro Cataliotti, Guido Boerrigter, Horng C Chen, Fernando L Martin, and John C Burnett Jr
Cardiorenal Enhancing and Aldosterone Suppressing Actions of a Novel Designer Natriuretic Peptide in Experimental Hypertension with Ventricular Pressure Overload Paul M McKie, Alessandro Cataliotti, Guido
More informationRenal physiology D.HAMMOUDI.MD
Renal physiology D.HAMMOUDI.MD Functions Regulating blood ionic composition Regulating blood ph Regulating blood volume Regulating blood pressure Produce calcitrol and erythropoietin Regulating blood glucose
More informationPotential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial
European Heart Journal (2006) 27, 2982 2988 doi:10.1093/eurheartj/ehl403 Clinical research Coronary heart disease Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian
More informationSafa Al Therwani *, Frank Holden Mose, Janni Majgaard Jensen, Jesper Nørgaard Bech and Erling Bjerregaard Pedersen
Al Therwani et al. BMC Nephrology 2014, 15:100 RESEARCH ARTICLE Open Access Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition
More informationSpecial Lecture 11/08/2013. Hypertension Dr. HN Mayrovitz
Special Lecture 11/08/2013 Hypertension Dr. HN Mayrovitz Arterial Blood Pressure (ABP) Major Factors Summarized Sympathetic Hormones Arteriole MAP ~ Q x TPR + f (V / C) SV x HR Renal SBP Hypertension =
More information(dyslipidemia) (CKD) (hypercholesterolemia) (hypertriglyceridemia) (CVD) B (apolipoprotein(apo)b) (VLDL) (HDL) ( VLDL)
(dyslipidemia) (CKD) (CVD) (CKD) (nephrotic syndrome) (dyslipidemia) (proteinuria) (hypercholesterolemia) (hypertriglyceridemia) B (apolipoprotein(apo)b) (VLDL) (IDL)(LDL) (HDL) ( VLDL) (HDL-C) LDL-C HDL-C
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationBlood Pressure Fox Chapter 14 part 2
Vert Phys PCB3743 Blood Pressure Fox Chapter 14 part 2 T. Houpt, Ph.D. 1 Cardiac Output and Blood Pressure How to Measure Blood Pressure Contribution of vascular resistance to blood pressure Cardiovascular
More informationRenal Quiz - June 22, 21001
Renal Quiz - June 22, 21001 1. The molecular weight of calcium is 40 and chloride is 36. How many milligrams of CaCl 2 is required to give 2 meq of calcium? a) 40 b) 72 c) 112 d) 224 2. The extracellular
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More informationPhysiology (4) 2/4/2018. Wael abu-anzeh
Physiology (4) 2/4/2018 Wael abu-anzeh In the previous lectures we have discussed the filtration and the reabsorption processes but in this lecture we will talk about the factor that will regulate or control
More informationRegulation of fluid and electrolytes balance
Regulation of fluid and electrolytes balance Three Compartment Fluid Compartments Intracellular = Cytoplasmic (inside cells) Extracellular compartment is subdivided into Interstitial = Intercellular +
More informationBASELINE CHARACTERISTICS OF THE STUDY POPULATION
COMPARISON OF TREATING METABOLIC ACIDOSIS IN CKD STAGE 4 HYPERTENSIVE KIDNEY DISEASE WITH FRUITS & VEGETABLES OR SODIUM BICARBONATE This was a 1-year, single-center, prospective, randomized, interventional
More informationThe role of statins in patients with arterial hypertension
Invited review The role of statins in patients with arterial hypertension Trygve B. Tjugen 1, Sigrun Halvorsen 1, Reidar Bjørnerheim 1, Sverre E. Kjeldsen 1, 2 1University of Oslo, Department of Cardiology,
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationBODY FLUID. Outline. Functions of body fluid Water distribution in the body Maintenance of body fluid. Regulation of fluid homeostasis
BODY FLUID Nutritional Biochemistry Yue-Hwa Chen Dec 13, 2007 Chen 1 Outline Functions of body fluid Water distribution in the body Maintenance of body fluid Intake vs output Regulation of body fluid Fluid
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More informationTiny Jaarsma Linköping University No conflict of interest
Detrimental effects of sodium in heart failure - Tiny Jaarsma Linköping University No conflict of interest Sodium restriction in Heart Failure Why? Prevention of heart failure Blood pressure treatment
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationProf. Andrzej Wiecek Department of Nephrology, Endocrinology and Metabolic Diseases Medical University of Silesia Katowice, Poland.
What could be the role of renal denervation in chronic kidney disease? Andrzej Wiecek, Katowice, Poland Chairs: Peter J. Blankestijn, Utrecht, The Netherlands Jonathan Moss, Glasgow, UK Prof. Andrzej Wiecek
More informationHYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL
HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR
More informationErling B Pedersen 1,2,3*, Ingrid M Thomsen 2, Thomas G Lauridsen 1. Abstract
RESEARCH ARTICLE Open Access Abnormal function of the vasopressin-cyclic-ampaquaporin2 axis during urine concentrating and diluting in patients with reduced renal function. A case control study Erling
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationIntroduction to the kidney: regulation of sodium & glucose. Dr Nick Ashton Senior Lecturer in Renal Physiology Faculty of Biology, Medicine & Health
Introduction to the kidney: regulation of sodium & glucose Dr Nick Ashton Senior Lecturer in Renal Physiology Faculty of Biology, Medicine & Health Objectives Overview of kidney structure & function Glomerular
More informationSLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota
SLOWING PROGRESSION OF KIDNEY DISEASE Mark Rosenberg MD University of Minnesota OUTLINE 1. Epidemiology of progression 2. Therapy to slow progression a. Blood Pressure control b. Renin-angiotensin-aldosterone
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationRENAL SYSTEM 2 TRANSPORT PROPERTIES OF NEPHRON SEGMENTS Emma Jakoi, Ph.D.
RENAL SYSTEM 2 TRANSPORT PROPERTIES OF NEPHRON SEGMENTS Emma Jakoi, Ph.D. Learning Objectives 1. Identify the region of the renal tubule in which reabsorption and secretion occur. 2. Describe the cellular
More informationTraitements associés chez l hypertendu: Statines, Aspirine
Traitements associés chez l hypertendu: Statines, Aspirine Pr Jean-Jacques Mourad CHU Avicenne, Université Paris 13, Bobigny DU HTA, Mars 2012 jean-jacques.mourad@avc.aphp.fr Global Mortality 2000: Impact
More informationAJH 1998;11: by the American Journal of Hypertension, Ltd /98/$19.00
AJH 1998;11:8 13 Acute Effects of Intravenous Sodium Chloride Load on Calcium Metabolism and on Parathyroid Function in Patients With Primary Aldosteronism Compared With Subjects With Essential Hypertension
More informationBIOL 2402 Renal Function
BIOL 2402 Renal Function Dr. Chris Doumen Collin County Community College 1 Renal Clearance and GFR Refers to the volume of blood plasma from which a component is completely removed in one minute by all
More informationAllopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease
Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease Michelle P Kao, Donald S Ang, Steve Gandy, Chim C Lang, Allan D Struthers Division of
More informationUric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George
Uric acid and CKD Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George Hospital @Badves Case Mr J, 52 Male, referred in June 2015 DM type 2 (4 years), HTN, diabetic retinopathy, diabetic
More informationION CHANNELS MEMBRANE TRANSPORT INTEGRATIVE PHYSIOLOGY
Kidney International, Vol. 63 (2003), pp. 1417 1425 ION CHANNELS MEMBRANE TRANSPORT INTEGRATIVE PHYSIOLOGY Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationEffect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial
Larsen et al. BMC Nephrology 2013, 14:163 RESEARCH ARTICLE Open Access Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled
More informationManaging High Blood Pressure Naturally. Michael A. Smith, MD Life Extension s Healthy Talk Series
Managing High Blood Pressure Naturally Michael A. Smith, MD Life Extension s Healthy Talk Series Part 1 What is Blood Pressure? Blood Pressure Systole Systolic Forward Pressure 110 mmhg 70 mmhg Diastole
More informationCounter-Current System Regulation of Renal Functions
Counter-Current System Regulation of Renal Functions Assoc. Prof. MUDr. Markéta Bébarová, Ph.D. Department of Physiology Faculty of Medicine, Masaryk University This presentation includes only the most
More informationSalt Sensitivity: Mechanisms, Diagnosis, and Clinical Relevance
Salt Sensitivity: Mechanisms, Diagnosis, and Clinical Relevance Matthew R. Weir, MD Professor and Director Division of Nephrology University of Maryland School of Medicine Overview Introduction Mechanisms
More informationBlood Pressure Regulation. Faisal I. Mohammed, MD,PhD
Blood Pressure Regulation Faisal I. Mohammed, MD,PhD 1 Objectives Outline the short term and long term regulators of BP Know how baroreceptors and chemoreceptors work Know function of the atrial reflex.
More informationTHE EFFECTS OF AN ANGIOTENSIN BLOCKER (SARALASIN) ON KIDNEY FUNCTION IN DEHYDRATED SHEEP
Quarterly Journal of Experimental Physiology (1982) 67, 97-103 Printed in Great Britain THE EFFECTS OF AN ANGIOTENSIN BLOCKER (SARALASIN) ON KIDNEY FUNCTION IN DEHYDRATED SHEEP NANCY E. YESBERG, MYRNA
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationCardiorenal and Renocardiac Syndrome
And Renocardiac Syndrome A Vicious Cycle Cardiorenal and Renocardiac Syndrome Type 1 (acute) Acute HF results in acute kidney injury Type 2 Chronic cardiac dysfunction (eg, chronic HF) causes progressive
More informationFluid and electrolyte balance, imbalance
Fluid and electrolyte balance, imbalance Body fluid The fluids are distributed throughout the body in various compartments. Body fluid is composed primarily of water Water is the solvent in which all solutes
More informationVariability in drug response: towards more personalized diabetes care Petrykiv, Sergei
University of Groningen Variability in drug response: towards more personalized diabetes care Petrykiv, Sergei IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you
More informationAssessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation
Nephrol Dial Transplant (2002) 17: 1909 1913 Original Article Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new () prediction equation
More informationThe principal functions of the kidneys
Renal physiology The principal functions of the kidneys Formation and excretion of urine Excretion of waste products, drugs, and toxins Regulation of body water and mineral content of the body Maintenance
More informationOriginal Article. Introduction
Nephrol Dial Transplant (2006) 21: 3106 3114 doi:10.1093/ndt/gfl244 Advance Access publication 23 May 2006 Original Article The effect of statins on urinary albumin excretion and glomerular filtration
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationKlotho: renal and extra-renal effects
Klotho: renal and extra-renal effects Juan F. Navarro-González, MD, PhD, FASN Nephrology Service and Research Division University Hospital Nuestra Señora de Candalaria Santa Cruz de Tenerife. Spain Klotho:
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationEffect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease
Scandinavian Journal of Urology and Nephrology, 2010; 44: 56 61 ORIGINAL ARTICLE Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease ROBERT
More information1.6 > < ESRD. < >2.0 ESRD Serum creatinine mg/dl
HMG-CoA Reductase Inhibitors and Renal Function Vito M. Campese, MD Professor of Medicine, Physiology and Biophysics Chief, Division of Nephrology and Hypertension Center Keck School of Medicine, USC Los
More informationOver- and underfill: not all nephrotic states are equal. Detlef Bockenhauer
Over- and underfill: not all nephrotic states are equal Detlef Bockenhauer Objectives Review pathophysiology of oedema: undervs overfill Treatment options The clinical setting: case 1 A6-y old girl with
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More information*Sections or subsections omitted from the full prescribing information are not listed.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GIAPREZA TM safely and effectively. See full prescribing information for GIAPREZA. GIAPREZA (angiotensin
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationBASELINE CHARACTERISTICS OF THE STUDY POPULATION
Study Summary DAILY ORAL SODIUM BICARBONATE PRESERVES GLOMERULAR FILTRATION RATE BY SLOWING ITS DECLINE IN EARLY HYPERTENSIVE NEPHROPATHY This was a 5-year, single-center, prospective, randomized, placebo-controlled,
More informationLaunch Meeting 3 rd April 2014, Lucas House, Birmingham
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Launch Meeting 3 rd April 2014, Lucas House, Birmingham Prof Sunil Bhandari
More informationHypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease
Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease July 2017 Indranil Dasgupta DM FRCP, Debasish Banerjee MD
More informationMetabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology
Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient
More informationSupplementary Online Content
Supplementary Online Content Xu X, Qin X, Li Y, et al. Efficacy of folic acid therapy on the progression of chronic kidney disease: the Renal Substudy of the China Stroke Primary Prevention Trial. JAMA
More informationI t has been reported recently that of 4483 apparently
728 ORIGINAL ARTICLE The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease
More information(KFTs) IACLD CME, Monday, February 20, Mohammad Reza Bakhtiari, DCLS, PhD
Kidney Function Tests (KFTs) IACLD CME, Monday, February 20, 2012 Mohammad Reza Bakhtiari, DCLS, PhD Iranian Research Organization for Science & Technology (IROST) Tehran, Iran Composition and Properties
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationEntresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction
Cardio-Metabolic Franchise Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Randy L Webb, PhD Rutgers Workshop October 21, 2016 Heart
More informationProceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009
www.ivis.org Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009 São Paulo, Brazil - 2009 Next WSAVA Congress : Reprinted in IVIS with the permission of the Congress Organizers PROTEINURIA
More informationMeta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes
et al. British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2003.02060.x Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes Bernard
More informationThe kidney. (Pseudo) Practical questions. The kidneys are all about keeping the body s homeostasis. for questions Ella
The kidney (Pseudo) Practical questions for questions Ella (striemit@gmail.com) The kidneys are all about keeping the body s homeostasis Ingestion Product of metabolism H 2 O Ca ++ Cl - K + Na + H 2 O
More informationRENAL FUNCTION An Overview
RENAL FUNCTION An Overview UNIVERSITY OF PNG SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL MBBS II SEMINAR VJ. Temple 1 Kidneys
More informationKD02 [Mar96] [Feb12] Which has the greatest renal clearance? A. PAH B. Glucose C. Urea D. Water E. Inulin
Renal Physiology MCQ KD01 [Mar96] [Apr01] Renal blood flow is dependent on: A. Juxtaglomerular apparatus B. [Na+] at macula densa C. Afferent vasodilatation D. Arterial pressure (poorly worded/recalled
More informationrenoprotection therapy goals 208, 209
Subject Index Aldosterone, plasminogen activator inhibitor-1 induction 163, 164, 168 Aminopeptidases angiotensin II processing 64 66, 214 diabetic expression 214, 215 Angiotensin I intrarenal compartmentalization
More information